In vivo effects of three calcium blockers on chickens with inherited muscular dystrophy.
Genetically homozygous Line 413 dystrophic chickens were given in separate trials daily i.p. injections of aqueous solutions of the calcium blocker drugs, diltiazem, verapamil, or nifedipine. At a dosage of 20 mg/kg/day, drug therapy in each case significantly prolonged the functional ability of the dystrophic chickens as quantitated regularly by a standardized test for righting ability. Enhanced functional ability, however, was not generally accompanied by a decrease in the usually high plasma creatine kinase activity. In addition, there was no change in the pectoralis muscle mass or protein with any of the drug treatments. Moreover, no significant reduction in the abnormally high total muscle calcium was found with calcium blocker treatment. Also, there was no marked change in the histopathology of muscle from the drug-treated dystrophic chickens. We concluded that drugs with calcium entry blocker activity offer only limited benefit in retarding dystrophic symptoms expressed in the chicken (viz., short-term enhancement in righting ability).
D000818:Animals; D001552:Benzazepines / Q000627:therapeutic use*; D002118:Calcium / Q000032:analysis; D002645:Chickens / Q000235:genetics; D003402:Creatine Kinase / Q000378:metabolism; D004110:Diltiazem / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009132:Muscles / Q000032:analysis; D009136:Muscular Dystrophies / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D009543:Nifedipine / Q000627:therapeutic use*; D014700:Verapamil / Q000627:therapeutic use*
D001552:Benzazepines; D014700:Verapamil; D003402:Creatine Kinase; D004110:Diltiazem; D009543:Nifedipine; D002118:Calcium